Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MGC Pharmaceuticals (MXC) receives study and import approvals from the South African Health Products Regulatory Authority for the Phase IIb CimetrA trial
  • The trial will aim to target the effects of viral infections with inflammatory complications in patients with moderate COVID-19
  • Once completed, the trial will provide the data needed to plan future regulatory pathways to register CimetrA as a drug
  • CimetrA is MGC’s natural, immune-modulation formula that is made up of vitamin C and herbal extracts used to treat anti-inflammatory illnesses
  • MGC Pharma is trading 11.1 per cent higher on the market at 2 cents at 2:52 pm AEST

MGC Pharmaceuticals (MXC) has been granted study and import approvals from the South African Health Products Regulatory Authority for the Phase IIb CimetrA trial.

The trial will aim to target the effects of viral infections with inflammatory complications in patients with moderate COVID-19.

It will determine the most effective dosage concentrations of the active ingredients and collect data to further validate CimetrA’s anti-inflammatory and immune-modulatory effects.

Once completed, the trial will provide further data for claims on the product as an investigational medical product and will provide data needed to plan future regulatory pathways to register CimetrA as a drug.

CimetrA is made up of artemisinin, a drug from a fern-like plant that is used against malaria, and curcumin, a chemical that aids in anti-inflammatory and antioxidants.

It is then mixed with vitamin C and boswellia serrata, a herbal extract used to treat inflammatory illnesses.

It can come in either a solid or a liquid form and has antioxidant, anti-inflammatory and immuno-modulating properties.

“With COVID-19 cases once again on the rise, the extension of the CimetrA dosage trial into South Africa could not be more important,” Co-Founder and Managing Director Roby Zomer commented.

“Clinical trials to date have demonstrated the efficacy of CimetrA against COVID-19, so it is crucial that we are able to complete the dosage trials in Israel and now South Africa as quickly as possible to we can move to the next stage of the clinical pipeline and treat those suffering from the effects of the cytokine storm and ‘long COVID’ more effectively.”

MGC Pharma was trading 11.1 per cent higher on the market at 2 cents at 2:52 pm AEST.

MXC by the numbers
More From The Market Herald
MetalsGrove Mining (ASX:MGA) - Managing Director, Sean Sivasamy

" MetalsGrove Mining (ASX:MGA) begins soil sampling at Upper Coondina

MetalsGrove Mining (ASX:MGA) has begun a soil sampling program at its Upper Coondina lithium project in…
Bellavista Resources (ASX:BVR) - Non Executive Chairman, Mel Ashton

" Bellavista Resources (ASX:BVR) commissions second rig for Brumby, WA

Bellavista Resources (ASX:BVR) has commissioned a second rig to begin drilling at its Brumby zinc-silver-copper project…

" Sky Metals (ASX:SKY) encounters further tin mineralisation at Tallebung, NSW

Sky Metals (ASX:SKY) has reported further tin mineralisation at its Tallebung tin project in New South…
Spectur (ASX:SP3) - Managing Director, Gerard Dyson

" Spectur (ASX:SP3) raises $1.15m in SPP

Spectur (ASX:SP3) has raised $1.15 million through a security purchase plan (SPP) and shortfall offer.